Baird Maintains Neutral Rating for GoodRx Holdings: Here's What You Need To Know

Baird has decided to maintain its Neutral rating of GoodRx Holdings GDRX and lower its price target from $7.00 to $6.00.

Shares of GoodRx Holdings are trading up 6.94% over the last 24 hours, at $6.32 per share.

A move to $6.00 would account for a 5.06% decline from the current share price.

About GoodRx Holdings

GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company's primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.